Medical Oncology

Myelodysplastic Syndromes

Questions discussed in this category

Does isolated del(5q) have the same prognostic implications for post-PV secondary myelofibrosis as it does in MDS?

Given the rarity of this in MF, is it still predictive of response to lenalidomide therapy?

1 Answer available

What is your preferred first line treatment for patients with high risk MDS who are not candidates for transplant?

1 Answer available

What is the best strategy after initial treatment with hypomethylating agents for high grade myelodysplatic syndromes, mainly for responders who became transfusion independent?

Do we continue the hypomethylating agent indefinitely?

1 Answer available

How do you choose between azacitidine and decitabine when deciding to treat a patient with MDS with a hypomethylating agent?

1 Answer available

Papers discussed in this category

The Lancet. Oncology, 2009-03

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002-05-15

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

Cancer, 2011-06-15

Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes.

American journal of hematology, 2009-09

A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes.

Cancer, 2010-08-15

Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy.

The New England journal of medicine, 2016-11-24

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

The Lancet. Haematology, 2018-01

Eltrombopag reduces clinically relevant thrombocytopenic events in higher risk MDS and AML.

Related Topics in Medical Oncology